InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,626.02
(
0.54%
)
US TECH 100
18,963.20
(
-0.27%
)
Dow Jones
41,393.78
(
0.72%
)
Brent Oil
71.82
(
0.60%
)
Bitcoin
58,674.78
(
-0.85%
)
Post# of 253125
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jb_118

Send PM Follow Ignore
Followers 0
Posts 253
Boards Moderated 0
Alias Born 03/01/2006

jb_118

Re: DewDiligence post# 123561

Tuesday, 07/19/2011 2:15:30 PM

Tuesday, July 19, 2011 2:15:30 PM

Post# of 253125

2Q11 generic Lovenox sales = $284M:



Anybody care to hazard an EPS for MNTA based on this sales figure? I haven't been tracking the pass through to MNTA from gross mEnox sales, but seems like it is about 31% of gross, with about 23M in spend and about 51M outstanding shares, roughs out to $1.28/share. Should bring them up to about $3.88 EPS for the previous 4 quarters, for a trailing PE of ~5. Should end the Q with about $6/share cash and receivables.

It seems like others have modeled this more accurately. Anybody else have something less rough?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up